Back to search
Antineutrophil Cytoplasmic Antibody-associated Vasculitis
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Antineutrophil Cytoplasmic Antibody-associated Vasculitis trials may be worth asking aboutClinical trial pipeline · Data from ClinicalTrials.gov
See which Antineutrophil Cytoplasmic Antibody-associated Vasculitis trials may be worth asking aboutNorth America
Europe
Asia-Pacific
Rest of World
Trials may have sites in multiple countries. Filtering shows any trial with at least one site in the selected country.
As rare disease, vasculitis affects a small number of patients, the cohorts available in the literature are few and the pathophysiological mechanisms remain to…
The current state of knowledge on ANCA-associated vasculitis (AAV) indicates that it is a group of autoimmune diseases in which small blood vessels in various o…
The primary objective of this study is to evaluate the long-term safety of avacopan in participants with antineutrophil cytoplasmic antibody (ANCA)-associated v…
The main objective of this study is to explore the efficacy of avacopan in participants affected by AAV.
The primary objective of this study is to evaluate the safety and tolerability of tarperprumig in participants with newly diagnosed or relapsing anti-neutrophil…
Background: \- Vasculitis is a group of diseases that inflame and damage blood vessels and tissue. It can cause many medical problems. Few tests can diagnose t…
This study aims to investigate the efficacy and safety of depemokimab compared with mepolizumab in adults with relapsing or refractory EGPA receiving SoC therap…
The purpose of this study is to evaluate the efficacy and safety of iptacopan compared to standard of care (SOC) to induce and maintain remission in study parti…